LENZ Therapeutics (LENZ) Stock Forecast & Price Target

Compare

320 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LENZ Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

LENZ

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LENZ Stock 12 Month Forecast

Average Price Target

$56.60

▲(235.11% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for LENZ Therapeutics in the last 3 months. The average price target is $56.60 with a high forecast of $62.00 and a low forecast of $52.00. The average price target represents a 235.11% change from the last price of $16.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","63":"$63","30.75":"$30.8","41.5":"$41.5","52.25":"$52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,30.75,41.5,52.25,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.4,32.83076923076923,35.261538461538464,37.69230769230769,40.12307692307692,42.55384615384615,44.98461538461538,47.41538461538462,49.84615384615385,52.276923076923076,54.70769230769231,57.13846153846154,59.56923076923077,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.4,32.41538461538462,34.43076923076923,36.44615384615385,38.46153846153846,40.47692307692308,42.49230769230769,44.50769230769231,46.52307692307693,48.53846153846154,50.55384615384615,52.56923076923077,54.58461538461539,{"y":56.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.4,32.06153846153846,33.723076923076924,35.38461538461539,37.04615384615384,38.707692307692305,40.36923076923077,42.03076923076923,43.69230769230769,45.35384615384615,47.01538461538462,48.676923076923075,50.33846153846154,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$62.00

Average Price Target$56.60

Lowest Price Target$52.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

12/15/25

Overreaction to LENZ Therapeutics' Stock Decline Presents Buying Opportunity Despite Isolated Retinal Tear Incident

Matthew Caufield

H.C. Wainwright

$56

Buy

231.56%

Upside

Reiterated

12/15/25

LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event

Stacy Ku

TD Cowen

$60

Buy

255.24%

Upside

Reiterated

12/12/25

Yigal Nochomovitz

Citi

$52

Buy

207.87%

Upside

Reiterated

12/04/25

LENZ Therapeutics (LENZ) Receives a Buy from Citi

Biren Amin

Piper Sandler

$67→$62

Buy

267.08%

Upside

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), LENZ Therapeutics (NASDAQ: LENZ) and Teva Pharmaceutical (NYSE: TEVA)

Jason Gerberry

Bank of America Securities

$53

Buy

213.80%

Upside

Reiterated

10/03/25

Bank of America Securities Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

Marc Goodman

Leerink Partners

$36

Buy

113.14%

Upside

Reiterated

08/01/25

Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops

Gary Nachman

Raymond James

$39→$40

Buy

136.83%

Upside

Reiterated

07/31/25

Raymond James Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

Joseph Catanzaro

Mizuho Securities

$38

Buy

124.99%

Upside

Reiterated

03/20/25

LENZ Therapeutics (LENZ) Gets a Buy from Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

12/15/25

Overreaction to LENZ Therapeutics' Stock Decline Presents Buying Opportunity Despite Isolated Retinal Tear Incident

Matthew Caufield

H.C. Wainwright

$56

Buy

231.56%

Upside

Reiterated

12/15/25

LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event

Stacy Ku

TD Cowen

$60

Buy

255.24%

Upside

Reiterated

12/12/25

Yigal Nochomovitz

Citi

$52

Buy

207.87%

Upside

Reiterated

12/04/25

LENZ Therapeutics (LENZ) Receives a Buy from Citi

Biren Amin

Piper Sandler

$67→$62

Buy

267.08%

Upside

Reiterated

12/01/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), LENZ Therapeutics (NASDAQ: LENZ) and Teva Pharmaceutical (NYSE: TEVA)

Jason Gerberry

Bank of America Securities

$53

Buy

213.80%

Upside

Reiterated

10/03/25

Bank of America Securities Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

Marc Goodman

Leerink Partners

$36

Buy

113.14%

Upside

Reiterated

08/01/25

Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops

Gary Nachman

Raymond James

$39→$40

Buy

136.83%

Upside

Reiterated

07/31/25

Raymond James Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

Joseph Catanzaro

Mizuho Securities

$38

Buy

124.99%

Upside

Reiterated

03/20/25

LENZ Therapeutics (LENZ) Gets a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering LENZ Therapeutics

1 Month

xxx

Success Rate

6/8 ratings generated profit

Average Return

+4.58%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.58% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+13.66%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +13.66% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

5/11 ratings generated profit

Average Return

+1.76%

reiterated a buy rating 5 months ago

Copying Marc Goodman's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +1.76% per trade.

2 Years

xxx

Success Rate

1/8 ratings generated profit

Average Return

-29.78%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -29.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LENZ Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LENZ has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LENZ average Analyst price target in the past 3 months is 56.60.

Each month's total comprises the sum of three months' worth of ratings.

LENZ Financial Forecast

LENZ Earnings Forecast

Next quarter’s earnings estimate for LENZ is -$0.96 with a range of -$1.05 to -$0.80. The previous quarter’s EPS was -$0.59. LENZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.

LENZ Sales Forecast

Next quarter’s sales forecast for LENZ is $1.32M with a range of $0.00 to $4.09M. The previous quarter’s sales results were $12.50M. LENZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LENZ has Performed in-line its overall industry.

LENZ Stock Forecast FAQ

What is LENZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Lenz Therapeutics, Inc.’s 12-month average price target is 56.60.

What is LENZ’s upside potential, based on the analysts’ average price target?

Lenz Therapeutics, Inc. has 235.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LENZ a Buy, Sell or Hold?

Lenz Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Lenz Therapeutics, Inc.’s price target?

The average price target for Lenz Therapeutics, Inc. is 56.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $52.00. The average price target represents 235.11% Increase from the current price of $16.89.

What do analysts say about Lenz Therapeutics, Inc.?

Lenz Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of LENZ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

LENZ Therapeutics (LENZ) Stock Forecast & Price Target

LENZ Analyst Ratings

LENZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering LENZ Therapeutics

LENZ Analyst Recommendation Trends

LENZ Financial Forecast

LENZ Earnings Forecast

LENZ Sales Forecast

LENZ Stock Forecast FAQ

Detailed List of Analyst Forecasts